Anthracycline cardiotoxicity: from bench to bedside.
Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerbate the toxicity. The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, in Como, Italy, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs. Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues.
Gianni
Luca
L
Division of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori, Milan, Italy.
Herman
Eugene H
EH
Lipshultz
Steven E
SE
Minotti
Giorgio
G
Sarvazyan
Narine
N
Sawyer
Douglas B
DB
D000818:Animals; D018943:Anthracyclines / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004347:Drug Interactions; D020022:Genetic Predisposition to Disease; D006321:Heart / Q000187:drug effects* / Q000254:growth & development; D006331:Heart Diseases / Q000139:chemically induced* / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D023421:Models, Animal; D009206:Myocardium / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors
D018943:Anthracyclines; D000970:Antineoplastic Agents; D015415:Biomarkers; D036341:Intercellular Signaling Peptides and Proteins